Journal
CHEMICAL REVIEWS
Volume 116, Issue 11, Pages 6707-6741Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.chemrev.5b00656
Keywords
-
Categories
Funding
- NIH [(NIGMS, NIMH, NIDA)] [MH102548, U19MH106839, DA037207, GM106232, MH082867, DA023947, MH087965, MH097056, MH062646, MH074953, MH08465]
- Autism Speaks Treatment Award
- William K. Warren Foundation
Ask authors/readers for more resources
Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery, filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique conformations of the GPCR that afford fundamentally new receptors, capable of novel pharmacology, unprecedented subtype selectivity, and unique signal bias. This review provides a comprehensive overview of the basics of GPCR allosteric pharmacology, medicinal chemistry, drug metabolism, and validated approaches to address each of the major challenges and caveats. Then, the review narrows focus to highlight recent advances in the discovery of allosteric ligands for metabotropic glutamate receptor subtypes 1-5 and 7 (mGlu(1-5),(7)) highlighting key concepts (molecular switches, signal bias, heterodimers) and practical solutions to enable the development of tool compounds and clinical candidates. The review closes with a section on late-breaking new advances with allosteric ligands for other GPCRs and emerging data for endogenous allosteric modulators.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available